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Abstract
Background: In the Indian subcontinent, about 200 million people are at risk of developing visceral leishmaniasis (VL). In
2005, the governments of India, Nepal and Bangladesh started the first regional VL elimination program with the aim to
reduce the annual incidence to less than 1 per 10,000 by 2015. A mathematical model was developed to support this
elimination program with basic quantifications of transmission, disease and intervention parameters. This model was used
to predict the effects of different intervention strategies.
Methods and Findings: Parameters on the natural history of Leishmania infection were estimated based on a literature
review and expert opinion or drawn from a community intervention trial (the KALANET project). The transmission dynamic
of Leishmania donovani is rather slow, mainly due to its long incubation period and the potentially long persistence of
parasites in infected humans. Cellular immunity as measured by the Leishmanin skin test (LST) lasts on average for roughly
one year, and re-infection occurs in intervals of about two years, with variation not specified. The model suggests that
transmission of L. donovani is predominantly maintained by asymptomatically infected hosts. Only patients with
symptomatic disease were eligible for treatment; thus, in contrast to vector control, the treatment of cases had almost no
effect on the overall intensity of transmission.
Conclusions: Treatment of Kala-azar is necessary on the level of the individual patient but may have little effect on
transmission of parasites. In contrast, vector control or exposure prophylaxis has the potential to efficiently reduce
transmission of parasites. Based on these findings, control of VL should pay more attention to vector-related interventions.
Cases of PKDL may appear after years and may initiate a new outbreak of disease; interventions should therefore be long
enough, combined with an active case detection and include effective treatment.
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Introduction
Leishmaniasis is a vector-borne disease, which is caused by
protozoan flagellates and is transmitted by phlebotomine sand flies.
Clinical manifestations of leishmaniasis include cutaneous leish-
maniasis (CL), muco-cutaneous leishmaniasis (MCL), visceral
leishmaniasis(VL)and post-kala-azardermalleishmaniasis (PKDL).
The only life-threatening form is VL, which is strongly linked with
poor housing [1]. The majority of VL cases (.90%) occur in only
six countries: Bangladesh, India, Nepal, Sudan, Ethiopia and Brazil
[2].InEastAfrica andtheIndian subcontinent, the disease is caused
by L. donovani. In Europe, North Africa and Latin America L.
infantum predominates [3]. In the Indian subcontinent, about 200
million people are estimated to be at risk of developing VL; this
region harbours an estimated 67% of the global VL disease burden
[2]. In this region, VL has been endemic for many decades, withthe
first reported epidemic in Bengal in the 1820s [4].
Disease
VL, also called Kala-azar (KA), causes more than 50,000 deaths
each year worldwide [5]. The name ‘Kala-azar’ (‘black-fever’)
originates from India; it refers to the hyperpigmentation of the skin
during the course of the disease. In contrast to CL and MCL,
where the parasites are localised in tegumentary tissue, VL is a
systemic infection of the phagocytic and reticulo-endothelial
system; this infection includes the lymph nodes, spleen and liver.
Clinical symptoms of VL are prolonged fever, fatigue, weight loss,
bleeding tendency and an enlarged spleen and liver. Pancytopenia
is also a characteristic sign.
PKDL, first described by Brahmachari in 1922 [6], can occur as
a sequel to KA. It usually develops 6 months to several years after
treatment and putative recovery from KA [7]. Poor treatment
compliance is thought to favour the occurrence of PKDL [8], but
a small fraction of PKDL cases have no reported history of KA
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parasites [10]. PKDL is not a life-threatening condition, laboratory
confirmation is challenging, and the treatment burdens the patients
(in Bangladesh, current treatment guidelines call for 120 intramus-
cular injections of sodium stibogluconate [9]). Therefore, it is
assumedthat manypatientsremainundiagnosed and untreated,and
PKDL patients are thought to act as a reservoir of infection [11].
Cases with VL and HIV co-infection have been reported from
35 countries. Both cellular and humoral responses to Leishmania are
diminished in such patients [12], leading to an increased risk of
developing VL after Leishmania infection and a higher rate of
treatment failure [13,14]. The rate of HIV-VL coinfection in the
Indian subcontinent is still low but rising in Ethiopia. HIV-
coinfected patients are relevant for the study of transmission, as
they are more infectious due to higher parasitaemia [15].
Diagnostics
The classical confirmatory test for VL used to be the microscopic
detection of amastigote parasites from aspirates of lymph nodes,
bone marrow or spleen [16]. This invasive method has largely been
replaced by antibody-detection using rK39 immunochromato-
graphic tests or by the direct agglutination test (DAT) [2]. Several
PCR techniques have been developed. They seem to be more
sensitive for detecting asymptomatic infections than the antibody
tests [17], as it is hypothesised that PCR of peripheral blood will be
the first marker to become positive after infection (before antibody
seroconversion takes place). The leishmanin skin test (LST) is a
marker of the delayed-type hypersensitivity reaction and is used in
epidemiological surveys to study what proportion of the population
has become ‘immune’ to leishmanial infection after exposure.
Transmission cycle
When taking a bloodmeal on an infected host, female sand flies
ingest the amastigote form of the parasites. In the sand fly gut, the
parasites develop into procyclic promastigote flagellar forms,
which divide and later on differentiate into metacyclic promasti-
gotes. These forms migrate to the pharyngeal valve and can then
be transmitted at subsequent blood meals. In the human host,
parasites change back to amastigotes and multiply in cells of the
mononuclear phagocyte system, impeding the immune defence
mechanisms of macrophages [18].
Control strategies
In 2005, the governments of India, Nepal and Bangladesh
started the first regional VL elimination program, aiming to
reduce the annual incidence of VL to less than 1 per 10,000 by
2015. The program focuses on treatment-related control strategies,
such as early diagnosis and complete treatment, and vector-related
control strategies, including indoor residual insecticide spraying.
Treatment
Currently, four drugs for VL treatment are available. 1)
Pentavalent antimonials have been the first-line treatment for
over 70 years. This treatment is long (20 to 30 days), is toxic (3–5%
deaths due to treatment) and is accompanied by increasing failure
rates; for instance in foci of the Bihar state, India, with up to 60%
treatment failures, a phenomenon that is assumed to be caused by
drug resistance [19]. 2) Miltefosine is the first oral drug against VL
and has been recommended as first-line drug in the VL
elimination initiative but is teratogenic and is suspected to rapidly
give rise to resistance due to its long half-life. 3) Amphotericin B is
used in two formulations: ‘‘Conventional’’ Amphotericin B and
‘‘Liposomal’’ Amphotericin B (Ambisome). Treatment with the
conventional formulation is long (30 days) and can have life-
threatening side effects whereas treatment with the liposomal
formulation is shorter, has similar high efficacy and fewer side
effects; Yet it is too expensive and complex in its administration for
large-scale application in developing countries. However recently,
a single-dose Ambisome schedule was found highly effective in
India [20]. 4) Paromomycin (PMM) was registered in 2006 in
India and is currently being tested in a phase IV trial [2,21].
Vector control. Vector control is an effective tool for
controlling VL, as demonstrated in the 1950s in India by malaria
control with DDT. Indoor spraying, in particular, reduces sand fly
densities, also long-lasting insecticide-treated bed nets and to a
minor extent environmental management [22,23]. However, the
recent community intervention trial KalaNet failed to demonstrate
an effect of long-lasting insecticide-treated nets on the incidences of
L. donovani infection and VL [24].
Mathematical modelling
The first mathematical study of the dynamics of KA employed a
deterministic model to explain the observed inter-epidemic periods
between 1875 and 1950 in Assam, India [25]. This model was
later extended to canine visceral leishmaniasis in Malta,
considering three different serological tests for the presence of
specific antibody in dogs [26,27]. In a further extension, the
efficacies of various control methods, such as vaccination, killing
infected dogs, drugs and insecticides, were investigated by means
of sensitivity analyses [28]. A recent modelling paper addressed the
question of under-reporting of VL in Bihar, India. [29].
Our model focuses on the transmission dynamics of L. donovani
in the Indian subcontinent and extends the before-mentioned
modelling findings with (i) quantifications of epidemiological
parameters for the natural history of infection and transmission
dynamics of L. donovani and (ii) databased predictions for the effects
of different intervention strategies; in particular, the roles of
asymptomatic and symptomatic infections are considered.
Methods
Model
The transmission dynamics of L. donovani in the Indian
subcontinent was modelled deterministically by a system of
ordinary differential equations. Figure 1 describes the model
graphically, and Table 1, 2 and 3 provide lists of parameters and
Author Summary
Visceral Leishmaniasis is a neglected, life-threatening
disease affecting the poorest of the poor. It has received
more attention in light of the regional VL elimination
program. A deterministic compartmental model was
developed to estimate parameters for L. donovani trans-
mission and to optimise intervention success. Our
simulation results show that transmission of L. donovani
is predominantly driven by asymptomatically infected
hosts who are not eligible for treatment. Treatment can
reduce the prevalence of symptomatic disease, but the
incidence of KA remains on similar levels because of an
unchanged intensity of transmission. In contrast to
treatment-related interventions, vector-related interven-
tions have the potential to reduce the prevalence of
asymptomatic infections and thus are the intervention of
choice from an epidemiological perspective. Vector
control, however, should be combined with treatment,
as PKDL cases can act as reservoirs of infection. This
reservoir function originates from the long period of nearly
two years on average during which putatively recovered
KA patients develop PKDL.
Visceral Leishmaniasis Epidemiology and Control
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structure of the model; the full model, considering also possible
animal hosts and immuno-compromised humans, is provided in
Text S1 with Figure S1 showing the full model.
The basic Susceptible-Infected-Recovered (SIR) type model was
modified with respect to the history of infection, considering five
stages in the natural history of infection. These stages were
described based on different combinations of three diagnostic
markers to categorise people living in endemic areas: PCR (index
P, earliest marker for L. donovani infection), DAT (index D,
antibody response) and LST (index C, suggesting a state of
‘cellular’ immunity). Superscripts ‘‘+’’ and ‘‘2’’ represent positive
and negative results, respectively. If the infection proceeded
asymptomatically, we assumed that the human host (indicated by
subscript H) typically passed through the following five stages:
SH: Susceptible stage (P
2D
2C
2). Hosts are negative for all three
markers and can become infected in the future.
IHP: Early asymptomatic, infectious stage (P
+D
2C
2). The parasite
can be detected by PCR, but there is not yet any humoral or
cellular response in the host.
IHD: Late asymptomatic, infectious stage (P
+D
+C
2). Hosts are still
PCR-positive and antibodies can be detected by DAT.
Figure 1. Model for L. donovani infection, transmission and control. Compartments represent proportions in humans and vectors,
distinguished (vertically) according to their history of infection (defined by diagnostic states). The diagnostics comprised PCR, DAT and LST with
combinations shown in the bar on the left margin of the graph. Human hosts are further distinguished (horizontally) by disease and treatment status.
m1=mH+mK; m2=mH+mK+mT1; m3=mH+mK+mT2; for further variables and parameters see text, Table 1, Table 2, Table 3 and Table S1 in the Supplement.
doi:10.1371/journal.pntd.0001405.g001
Table 1. Model parameters and variables – sand flies.
Description Value Reference
NF No. of vectors per NH=100 humans, see below) 527 Estimated, 95% CI (347 to 990)
IF Equilibrium prevalence of infectious sand flies 0.5% [35,41,42]
1/mF Life expectancy of sand flies 14 days [43]
1/sF Sojourn time
1 of flies in the latent stage EF 5 days [44]
1/b Feeding cycle duration 4 days [36]
pH Probability that a human becomes infected when an infected
fly takes a blood meal on a susceptible person
1 Assumed (correlated with NF)
1Durations regardless of mortality, i.e., conditional on surviving (e.g. the sojourn time of flies in the latent stage EF would equal 1/(sF+sF) if mortality is considered).
doi:10.1371/journal.pntd.0001405.t001
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2D
+C
2). The parasite cannot be
detected anymore, but hosts are DAT-positive and not yet LST-
positive.
RHC: Late recovered stage (P
2D
2C
+). Hosts are DAT-negative
but still LST-positive and assumed to be protected against re-
infection.
Natural history of infection in humans. Humans are born
as susceptibles (SH) at a per capita birth rate aH. We assume a
constant population size NH based on constant birth and death
rates (mH). Susceptibles are infected at rate lH, that depends on 1)
the biting rate b of sand flies, 2) the probability of becoming
infected when being bitten by an infectious sand fly (pH) and 3) the
number of infectious sand flies per human (IF per NH).
After infection, humans enter the early asymptomatic stage IHP
and become PCR-positive in peripheral blood. Seroconversion
occurs at rate cHP into the late asymptomatic stage IHD, which is
characterised by the onset of DAT-positivity. If not dying, humans
remain in this asymptomatic stage for 1/cHD days. Infection with
Leishmania parasites proceeds in most cases asymptomatically,
with only a minor fraction of cases subsequently developing KA. A
major fraction fHR does not develop disease, becomes PCR-
negative in the early recovered stage RHD, and develops LST-
Table 2. Model parameters and variables – humans.
Description Value Reference
NH No. of humans 100 Scaling factor (in
relation to NF)
SH+RHC Prevalence* of PCR
2DAT
2
humans
76% KalaNet data
IHP Prevalence* of PCR
+DAT
2
humans
10% KalaNet data
IHD Prevalence* of PCR
+DAT
+
humans
2% KalaNet data
RHD Prevalence* of PCR
2DAT
+
humans
12% KalaNet data
IHS+IHT Prevalence* of symptomatic
KA
0.015% KalaNet data
IHL Prevalence* of PKDL 0.005% Model result based
on a fraction of
treatment failure
p2=3%
RHC Prevalence* of LST
+ humans 50% [31,32,33]
1/mH Baseline life expectancy of
humans
40 years Assumed
mK Excess mortality rate caused
by KA
1/(5 months) Assumed
pF1 Probability that a susceptible fly
becomes infected when feeding
on a human host of type IHP
0.0125 =pF2/2 (assumed)
pF2 Probability that a susceptible fly
becomes infected when feeding
on a human host of type IHD
0.025 Estimated, 95%
CI (0.012 to 0.038)
pF3 Probability that a susceptible fly
becomes infected when feeding
on a human host of type IHS, IHT1,
IHT2
1 Assumed
pF4 Probability that a susceptible fly
becomes infected when feeding
on a human host of type IHL
1 Assumed
fHS Fraction of asymptomatically
infected hosts (IHD) who will
develop symptomatic KA
0.33% Estimated, 95% CI
(0.22% to 0.49%)
fHL Fraction of asymptomatically
infected hosts (IHD) who will
develop PKDL
0.01% [9]: 8 cases in
22699 persons
during 6 years
fHR Fraction of asymptomatically
infected hosts (IHD) who will
recover without showing a
symptomatic course of
infection (RRHD)
99.77% =12(fHS+fHL)
1/cHP Sojourn time
1 in the early
asymptomatic stage IHP
60 days [37,45]
1/cHD Sojourn time
1 in the late
asymptomatic stage IHD
12 days Estimated, 95%
CI (9 to 15)
1/cHS Duration between diagnosis
of KA and onset of treatment
1 day Conditions in the
KalaNet trial
1/rHD Period
1 of DAT-positivity
in state RHD
74 days Estimated, 95%
CI (65 to 84)
1/rHT Period
1 of DAT-positivity
in state RHT
74 days =1/rHD (assumed)
1/rHC Period
1 of LST-positivity
in state RHC
307 days Estimated, 95% CI
(260 to 356)
*Prevalences include immuno-compromised humans.
1 Durations regardless of mortality.
doi:10.1371/journal.pntd.0001405.t002
Table 3. Model parameters and variables – treatment.
Description Value Reference
1/t1 Duration of first-line KA
treatment
30 days [21]
1/t2 Duration of second-line KA
treatment
30 days [21]
1/t3 Duration of PKDL treatment 180 days [9]
fT1 Fraction of treatment fatality 5% Personal
communication,
MB
mT1 Excess mortality rate caused by
first-line KA treatment
0.00167 =fTt1
mT2 Excess mortality rate caused by
second-line KA treatment
0.00167 =fTt2
p1 Fraction of KA patients not
responding to KA first-line
treatment (conditional on
surviving treatment, 12fT)
5% (100%
=p1+p2+p3)
[21]
p2 Fraction of KA patients who
appear to recover under KA
first-line treatment but will
develop PKDL (conditional on
surviving treatment, 12fT)
3% (100%
=p1+p2+p3)
Personal
communication,
MB
p3 Fraction of KA patients
recovering during KA
first-line treatment (conditional
on surviving treatment, 12fT)
92% (100%
=p1+p2+p3)
=12(p1+p2)
p4 Fraction of KA patients who
appear to recover under KA
second-line treatment but will
develop PKDL (conditional on
surviving treatment, 12fT)
3% (100%
=p4+p5)
=p2
p5 Fraction of KA patients
recovering during KA
second-line treatment
(conditional on surviving
treatment, 12fT)
97% (100%
=p4+p5)
=12p4
1/dHL Duration until relapse to PKDL 21 months [9,46,47]
For parameters and variables concerning immuno-compromised patients, see
Table S1.
doi:10.1371/journal.pntd.0001405.t003
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asymptomatic infections is split into a tiny fraction fHL of putatively
recovering humans who develop a state of PCR-negativity in
peripheral blood, while still harboring a non-detectable number of
parasites; this is denoted RHL, from where relapse to PKDL (IHL)
follows. A fraction (fHS) develops symptomatic KA (IHS) whilst
staying PCR-positive.
Therapy. The fraction fHS developing symptomatic KA (IHS)
is eligible for treatment. If not dying, these patients receive first-
line treatment (IHT1) on average after 1/cHS days. First-line
treatment (in state IHT1) is given for 1/t1 days. A proportion p3 of
patients clears parasites under first-line treatment, recovers
(RRHT), and finally becomes LST-positive (RRHC) like those
with asymptomatic infections. The remaining proportion 12p3 of
patients represents the treatment failures that are split into a PCR-
positive proportion of p1 KA patients receiving second-line
treatment (IHT2) and a proportion of p2 patients putatively
recovering into a state of PCR-negativity. The second
proportion still harbours a non-detectable number of parasites
(RHL, from where relapse to PKDL, IHL, will follow).
Second-line treatment (in state IHT2) is given for 1/t2 days. As
with first-line treatment, a proportion p5 of patients under second-
line treatment recovers (RRHT) and becomes LST-positive
(RRHC). The remaining proportion of p4 patients recovers
putatively into a state of PCR-negativity (RHL) from which, again,
relapse to PCR-positivity and PKDL (IHL) follows, for those who
do not die on average after 1/dHL days. All PKDL patients (IHL)
are treated until full recovery (RRHTRRHC).
Excess mortality 1) affects KA patients whose mortality rate
increases the baseline mortality rate mH to m1=mH+mK and 2)
occurs under treatment because of drug toxicity. Five percent of
patients die because of first-line or second-line treatment,
increasing the mortality rate to m2=mH+mK+mT1 or
m3=mH+mK+mT2. LST-positivity (suggesting a state of cellular
immunity) may remain over a period of 1/rHC days, after which
recovered humans (RHC) again become negative for all diagnostic
markers (RSH).
Vectors. We considered sand flies in the susceptible (SF),
latent (EF, not infectious), or infectious (IF) stages. Flies can become
infected by blood meals taken on infectious humans (IHP, IHD, IHS,
IHT1, IHT2, IHL). The infection rate lF of flies is determined by the
following: 1) the biting rate b, 2) the infection probabilities of flies
dependent on the infection status of the hosts (pF1 to pF4, see
Table 2) and 3) the numbers of infectious hosts.
We assumed that each blood meal of a susceptible sand fly leads
to a sand fly infection if taken from a symptomatically infected
human (pF3=100% for KA patients IHS, IHT1, IHT2 and
pF4=100% for PKDL patients IHL). For a sensitivity analysis, see
Results.
The probability that a fly becomes infected when feeding on
asymptomatically infected hosts of type IHP or IHD was estimated
with the model as follows. The infection probability pF2 of late
asymptomatically infected humans (IHD) was estimated, whereby
we assumed that the infectivity of hosts increases monotonically
from the time of infection until the late asymptomatic state IHD.
We defined an intermediate infection probability for flies
originating from hosts in the early asymptomatic state IHP as
pF1=pF2/2.
Data
KalaNet data. The model was fitted to data from the
KalaNet project (KALANET, ClinicalTrials.gov
NCT00318721), a community intervention trial in India and
Nepal to investigate the effectiveness of insecticide-treated bed
nets. The KalaNet trial was conducted between 2006 and 2008.
Around 35,000 cases of VL have been reported during this period
by the Government of India, Ministry of Health and Family
Welfare; thus, the prevalence of VL during the KalaNet trial was
lying almost in between the official numbers of 10,000 and 75,000
cases, respectively, after 1970 [30]. In the KalaNet trial,
consecutive blood samples were collected in 26 highly endemic
villages from 17,662 people older than two years. These blood
samples were used to diagnose infection of humans, by assessing
seroconversion with the direct agglutination test (DAT). Passive
and active detection for VL cases were conducted until May 2009.
In addition, blood samples for PCR analysis were collected (a) in a
random sub sample of all KalaNet villages from 625 people
between 15 and 40 years of age and (b) from all inhabitants older
than 3 years in one Nepalese KalaNet village (284 people).
Interventions in the KalaNet trial did not show an effect on VL
incidence and seroconversion; thus, we included data from
interventions and control clusters in our analyses. The KalaNet
data showed a prevalence of 12% PCR-positive (from 1,923
measurements on 909 individuals in total) and 14% DAT-positive
individuals (from 43,171 measurements on 17,662 individuals in
total). An intersection of 2% was positive for both markers (from
1,899 measurements on 893 individuals in total). Hence, 76% of
the population was negative for PCR and DAT. Confidence
intervals for these prevalences were not computed, as the large
sample size would suggest an unrealistically high precision. No
LST data were available in the KalaNet study. The average
incidence of symptomatic VL was 0.27% per year, with an
estimated prevalence of 0.015% (15 cases per 100,000). Definition
for symptomatic infection was adopted from the KalaNet project:
People with fever lasting for two weeks or more were examined by
a physician and tested with a rapid diagnostic test for VL [24].
Prevalence of Leishmania infection in sand flies as determined by
PCR was 0.5% in six Nepalese clusters.
Leishmanin skin test (LST). The before-mentioned
proportion of 76% of humans who are negative for PCR and
DAT includes 1) humans who either have never been infected
(susceptible newborns: aH NHRSH), 2) humans who recovered
from infection (RHRRHC), or 3) humans who have lost LST-
positivity thereafter (RHCRSH). We assumed that LST-positivity
could be lost because the consecutive PCR and DAT results of
several KalaNet participants showed re-infection (first positive,
then negative and then positive again). The prevalence of LST-
positive humans (RHC) was taken from published studies on LST in
Nepal [31], India [32] and Bangladesh [33], adopting an average
sensitivity of the LST of about 50% [33]. With these estimates, the
prevalence of 76% humans who are negative for PCR and DAT
can be split into a proportion of 50% LST-positive (RHC) and 26%
susceptible (SH). The effects emerging from variations in these
proportions will be discussed (see Discussion).
PKDL. There was no active detection for PKDL cases in the
KalaNet trial. The proportion of treatment failures among KA
patients under first- and second-line treatments who will develop
PKDL via a putatively recovered stage (IHT1 and IHT2RRHLRIHL)
is roughly 3% in India/Nepal (MB, personal communication),
which yields, together with a tiny proportion of asymptomatically
infected humans who develop PKDL without treatment
(IHDRRHLRIHL) [9], a prevalence of 0.5 PKDL cases per
10,000 (see Results). Putatively recovered KA patients develop
PKDL after 21 months on average [9].
Treatment. First- and second-line treatment lasts about 1
month for KA patients and about 6 months for PKDL patients.
For KA patients surviving treatment, a fraction of treatment
failure of 5% is assumed [9,21]. The effects emerging from
Visceral Leishmaniasis Epidemiology and Control
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analysis (see Results).
Parameter estimation
Model solutions were numerically computed using the software
Matlab Version 7.120635 (R2011a) by a Runge-Kutta algorithm
with variable step size (procedure ode15s). Parameters were
estimated by fitting the model to observations from the KalaNet
project (DAT- and PCR-positivity, symptomatic VL and sand fly
infection) and information from the literature (LST-positivity,
prevalence of HIV and prevalence of HIV-infected among symp-
tomatic VL).
We used the model to estimate the following eight parameters:
1. NF determining the density of sand flies (NF per NH)
2. 1/cHD determining the sojourn time in the late asymptomatic
stage IHD
3. 1/rHD determining the period of DAT-positivity in state RHD
4. 1/rHC determining the period of LST-positivity in state RHC
5. pF2 determining the probability that a fly becomes infected
when feeding on an asymptomatically infected human host in
state IHD
6. fHS determining the fraction of asymptomatically infected hosts
(IHD) who will develop KA
7. fVS determining the fraction of immuno-compromised and
asymptomatically infected hosts (IVD) who will develop
symptomatic KA (see Table S1)
8. g determining the HIV infection rate (see Table S1)
The parameter vector ~ h h~ NF,cHD,rHD,rHC,pF2,fHS,fVS,g ðÞ
was estimated by Maximum Likelihood with likelihood function
L~ IHSzIHT1zIHT2 ðÞ
k1
: SHzIHPzIHDzRHDzRHCzRHTzRHLzIHL ðÞ
k2
: IHDzIHLzRHDzRHTzRHL ðÞ
k3
: SHzIHPzRHC ðÞ
k4: IHP ðÞ
k5: IHDzIHL ðÞ
k6
: RHDzRHTzRHL ðÞ
k7: SHzRHC ðÞ
k8: RHC ðÞ
k9
: SHzIHPzIHDzRHDzRHTzRHLzIHL ðÞ
k10
: IVSzIVT1zIVT2 ðÞ
k11
: SVzIVPzIVDzRVDzRVCzRVTzRVLzIVL ðÞ
k12
: IVDzIVLzRVDzRVTzRVL ðÞ
k13: SVzIVPzRVC ðÞ
k14
: IVP ðÞ
k15: IVDzIVL ðÞ
k16: RVDzRVTzRVL ðÞ
k17
: SVzRVC ðÞ
k18: RVC ðÞ
k19
: SVzIVPzIVDzRVDzRVTzRVLzIVL ðÞ
k20
: IF ðÞ
k21: EFzSF ðÞ
k22,
where by exponents k1 to k22 represent sample sizes observed in
the KalaNet trial or taken from the literature (for references see
Table 1, 2, 3 and Table S1). These exponents are partially not
integer values, because sample sizes for the estimation had to be
back calculated considering the prevalence of HIV-positive hosts,
yielding
k1~24:96, k2~125545, k3~5743, k4~35061, k5~174:5,
k6~55:8, k7~342, k8~1311, k9~185:9, k10~186, k11~1:04,
k12~377, k13~17:2, k14~105:3, k15~0:524, k16~0:2,
k17~1:03,k18~3:94,k19~0:56,k20~0:56,k21~5:4, k22~1078:6:
The likelihood was maximized by minimizing the negative log-
Likelihood 2ln(L), using Matlab procedure fminsearch. Confi-
dence intervals were computed by the profile likelihood [34], i.e.
the parameter of interest was minimised (lower confidence limit) or
maximised (upper confidence limit) conditional on that the
likelihood worsens only according to x
2/2 with 1 degree of
freedom, i.e. 3.84/2, whereby the other 7 parameters may vary as
nuisance parameters. Parameter values, estimates and confidence
intervals are shown in Tables 1, 2, 3 and Table S1.
Results
Parameter estimates
The parameter estimates (Table 1, Table 2, Table 3 and Table
S1) originate from fitting the model to data of which prevalences
have been estimated as described in the Methods section were as
follows 26% of the human population (SH) were negative for all
three markers of PCR, DAT and LST (P
2D
2C
2), 10% (IHP) were
PCR-positive (P
+D
2C
2), 2% (IHD+IHS+IHT1+IHT2+IHL) were
PCR- and DAT-positive (P
+D
+C
2), 12% (RHD+RHT+RHL) were
DAT-positive (P
2D
+C
2) and 50% (RHC) were LST-positive
(P
2D
2C
+). Model-based rates and durations in the natural history
of infection were estimated from the prevalences for humans as
follows.
Humans remained on average 1/(lH+mH)=150 days in the
susceptible state (SH) before they became infected. After infection,
PCR-positivity lasted on average for 1/(cHP+mH)+1/(cHD+mH)=72
days (approx. 95% CI: 69 to 75 days) and overlapped with DAT-
positivity, which lasts for asymptomatic individuals for 1/
(cHD+mH)+1/(rHD+mH)=86 days (approx. 95% CI: 74 to 99 days).
For an overlap period of about 1/(cHD+mH)=12 days, asymptom-
atic individuals were positive for both markers (late asymptomatic
state IHD). This means that individuals without symptomatic
disease need on average about 146 days to develop LST-positivity
after a PCR-positive finding. LST-positivity lasted on average 1/
(rHC+mH)=300 days (approx. 95% CI: 255 to 348 days). As
population turnover alone is not sufficient to yield a prevalence of
26% susceptibles (negative for all three markers: P
2D
2C
2), loss of
LST-positivity must be assumed to explain these, together with a
prevalence of 50% LST-positive individuals in the population.
Taken these durations together, humans with an asymptomatic
course were infected on average every 596 days (=150 days
SH+60 days IHP+12 days IHD+74 days RHD+300 days RHC). As
heterogeneities are not taken into account, one might crudely
assume that humans become infected every one to three years.
Given a 0.5% prevalence of infected sand flies [35] and the
above-mentioned prevalences, the probability pF2 that a sand fly is
infected during a blood meal on an asymptomatic host (IHD) was
estimated at 2.5% with 95% CI (1.2% to 3.8%). This estimate is
robust against changes in the infection probability for flies feeding
on symptomatic hosts, which was assumed to be pF3=pF4=100%.
A sensitivity analysis in which pF3 and pF4 were reduced to 10% had
norelevant effectontheestimateforpF2, whichthen decreasedfrom
2.5% to 2.3%. The reason for this minor contribution of
symptomatically infected hosts to the overall transmission is simple:
Visceral Leishmaniasis Epidemiology and Control
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asymptomatically infected hosts. The estimates reported so far are
correlated with the time between blood meals of sand flies (assumed
with 1/b=4 days [36]) and the ratio NF:NH of vectors to humans
(estimated at 527:100, with 95% CINF (347 to 990)).
Intervention
We investigated interventions recommended by the VL elimina-
tion program, including treatment-related control strategies, such as
early case detection or treatment optimisation. We also considered
vector-related control strategies, such as breeding site control,
indoor spraying or use of bed nets, to explore possibilities and
constraints in VL control.
Treatment-related interventions. We used the model to
predict how different treatment regimens and early case detection
affect VL prevalence and incidence. Early case detection, e.g., due
to improved diagnosis, reduces the period of symptomatic KA
before the start of treatment. The existing drugs vary in their
treatment durations (from 30 days for antimonials and
conventional Amphotericin B to 5 days for Ambisome) and in
their recovery rates (from 99% for conventional Amphotericin B to
91% for Ambisome). We used seven model parameters to study
the effects of the different treatment-related interventions,
including the following: duration of first-line, second-line and
PKDL treatments (t1, t2, t3), duration of KA before treatment
(determined by cHS), the fraction of treatment fatality (fT) and
treatment failures leading to KA (p1) or PKDL (p2). Sensitivity
analyses were performed in ten different intervention scenarios (see
Table 4), and equilibrium solutions are shown in Fig. 2.
Fig. 2A shows that the different treatment regimens can only
reduce the prevalence of symptomatic infections, with almost no
effect on the prevalence of asymptomatic infections. The default
Figure 2. Treatment-related interventions. Sensitivity analyses of equilibrium solutions to the effects of seven intervention parameters (A) on
the prevalence of symptomatic (IHS, IHT1, IHT2, IHL) and asymptomatic infections (IHP, IHD) and (B) on the incidences of KA and PKDL. The ten scenarios
refer to ten parameter combinations as shown in Table 4. The default scenario 1 used parameter values as obtained from model calibration. The
duration of treatment (parameters t1, t2, t3) varied in scenarios 3 and 4; early case detection (1/cHS) varied in scenarios 5, 6, and 7; and treatment
efficacy (fT, p1, p2) varied in scenarios 8, 9 and 10. Scenario 2 represents a best-case scenario, using over-optimistic assumptions for all parameters. The
default scenario 1 was compared to more pessimistic intervention parameters in scenarios 5, 6 and 7 and to more optimistic intervention parameters
in scenarios 2, 3, 8, 9 and 10. As illustrated by the diagonally proceeding arrow, an optimal intervention would reduce the prevalence and incidence in
both dimensions (see Fig. 3 and Table 5 for vector-related interventions).
doi:10.1371/journal.pntd.0001405.g002
Table 4. Parameter combinations of treatment-related interventions.
Scenario
Parameter Default 1 2 3 4567891 0
Duration first-line treatment 1/t1 (days) 3 0 155 30 30 30 30 30 30
Duration second-line treatment 1/t2 (days) 3 0 155 30 30 30 30 30 30
Duration PKDL treatment 1/t3 (days) 180 1 30 180 180 180 180 180 180 180
Early case detection 1/cHS (days) 11 11 42 90 365 111
Treatment fatality fT (%) 50 5 55550 55
Treated fraction leading to retention of KA p1 (%) 50 5 555550 5
Treated fraction leading to relapse into PKDL p2 (%) 30 3 3333330
Ten different scenarios were considered for sensitivity analyses of the equilibrium solutions to the effects of seven treatment-related intervention parameters.
doi:10.1371/journal.pntd.0001405.t004
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not influenced much by the treatment fatality rate or by the
failure rates under KA and PKDL treatments (scenarios 8, 9 and
10). A prolonged period of symptomatic KA before treatment
increased the prevalence of symptomatic infections (scenarios 5, 6
and 7). The prevalence of symptomatic infections could be
reduced to 0.01% if successful KA treatment does not require a
treatment duration of 30 but 5 days (scenario 4); a further
reduction to 0.004% could be achieved by additionally reducing
the duration of successful PKDL treatment from 180 to 30 days
(scenario 3). Even under overoptimistic assumptions for all
treatment parameters, the treatment does not seem to be capable
of reducing the prevalence of symptomatic infection below
0.001% (scenario 2).
Fig. 2B shows the influence of the different treatment regimens
on the incidences of KA and PKDL. Improvements in treatment
could reduce the incidence of PKDL but have only a minor effect
on the incidence of KA. In a best-case scenario without any
treatment failures developing PKDL, the incidence of PKDL
could be reduced from about 1 case per 10,000 person-years
(scenario 1) to 0.6 cases per 10,000 person-years (scenarios 2, 10)
when there is no history of KA. A delay between case detection
and onset of treatment could only marginally lower the incidence
of PKDL but slightly increased the incidence of KA (scenarios 5, 6
and 7). In these scenarios, more KA patients died without having
received treatment; i.e., the lower incidence of PKDL must be
attributed to KA deaths.
These results suggest that transmission of KA is predominantly
driven by asymptomatically infected hosts who are not eligible for
treatment. Treatment can reduce the prevalence of symptomatic
disease, but the incidence of KA still remains on comparable
levels. For a given treatment efficacy, shorter treatment durations
reduced the patients’ treatment burden but had little effect on the
overall intensity of transmission.
Vector-related interventions. We selected three model
parameters to study the effects of breeding site control, indoor
spraying and use of bed nets, the effects of which were interpreted
in terms of the model as follows. Breeding site control was assumed
to reduce the vector population size NF, indoor spraying was
assumed to shorten the life expectancy 1/mF of sand flies, and the
universal use of untreated bed nets was assumed to lower the
contact rate b. Sensitivity analyses were performed on these three
model parameters in ten different intervention scenarios (see
Table 5), assuming that the interventions were applied equally to
all humans. Equilibrium solutions are shown in Fig. 3.
Figs. 3A and B demonstrate that, in contrast to treatment,
vector-based interventions reduce the prevalence of symptomatic
and asymptomatic infections, which implies that the incidences of
Figure 3. Vector-related interventions. Sensitivity analyses into the effects of vector control: (A) on the prevalence of symptomatic and
asymptomatic infections and (B) on the incidences of KA and PKDL. The scenarios refer to ten parameter combinations shown in Table 5. The default
scenario 1 uses parameter values as obtained from model calibration. Vector population size NF varied in scenarios 2 and5; the flies’ life expectancy 1/mF
varied in scenarios 3 and 6; and their feeding cycle duration 1/b varied in scenarios 4 and 7. Scenarios 8, 9 and 10 represent combinations thereof.
doi:10.1371/journal.pntd.0001405.g003
Table 5. Parameter combinations of vector-related interventions.
Scenario
Parameter Default 1 234567891 0
No. of vectors (NF)p e rNH=100 humans 527 100 527 527 300 527 527 300 300 527
Life expectancy of sand flies 1/mF (days) 14 14 7 14 14 11 14 11 14 11
Feeding cycle duration 1/b (days) 4 448 446 4 66
Ten different scenarios were considered for sensitivity analyses of the equilibrium solutions to the effects of three vector-related intervention parameters.
doi:10.1371/journal.pntd.0001405.t005
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by decreasing the vector density from NF=5.27 to 1 fly per human
host, by halving the sand flies’ life expectancy from 1/mF=14 days
to 7 days, or by increasing their feeding cycle duration from 1/
b=4 days to 8 days (scenarios 2, 3 and 4). Combinations of
feeding cycle duration of, for example, 6 days with a vector density
of 3 flies per human, or a life expectancy of 11 days also lead to
elimination (scenarios 9 and 10). Changes in parameter values had
an almost linear effect on prevalence and incidence, so the effect of
intermediate parameter values could be crudely derived by
interpolation (scenarios 5, 6, 7, 8).
The equilibrium solutions shown in Fig. 3 and Table 5 should
not be misleading in the sense that the dynamic properties of
transmission and control can be neglected. We therefore illustrated
the effect of reducing the contact rate (scenario 4 of Fig. 3 and
Table 5) in its time-dependent solution as shown in Fig. 4. The
prevalences of KA and PKDL could be effectively reduced by
means of vector control, but the effect on PKDL was delayed
because putatively recovered KA patients may relapse to PKDL
after months to years. This finding implies that an effective
reduction in the prevalence of PKDL will become apparent only
after years. After the intervention is stopped and the biting rate
reaches default values, the few remaining infectious people can
initiate a new outbreak of the disease.
Discussion
Visceral Leishmaniasis is a neglected, life-threatening disease
affecting the poorest of the poor, as this vector-borne disease is
strongly linked to poor housing [1]. Leishmaniasis has received
more attention in light of the regional VL elimination program. A
deterministic compartmental model was developed to estimate
parameters for L. donovani transmission and to optimise interven-
tion success. Uncertainties originating from a high-dimensional
parameter space and resulting correlations between parameters
have been explored by means of sensitivity analyses (see section on
sensitivity analyses at the end of Discussion). For instance, varying
the life expectancy of humans from 40 years to between 30 and 60
years did not change the estimates in a relevant way. Furthermore,
uncertainties can originate from spatial heterogeneities, which are
not included in this modelling approach (see Discussion about
clustered infection in the following section). Parameter estimates
(see Table 1, Table 2, Table 3 and Table S1) were derived from
fitting the model to database average prevalences, under the
assumption of homogeneous spread of the parasites within the
human and fly populations.
Natural history of infection
The transmission dynamics of L. donovani are rather slow, mainly
due to the long incubation period and the potentially long
persistence of parasites in infected humans. Parasite DNA can be
detected in infected human hosts for two to three months; after
seroconversion, antibodies can be detected for about the same
period of time in those humans who do not evolve to clinical
disease. These periods overlap for a few weeks only, when both
parasites and antibodies are detectable in peripheral blood. Few
infected humans become clinically sick. The majority of infected
hosts are estimated to become LST-positive five to six months after
infection, without showing any sign of disease. LST-positivity,
which is assumed to represent a state of protective cellular
immunity, is estimated to persist for about one year. Without loss
of LST-positivity, the model would lead under realistic birth and
death rates of humans to over 90% LST-positive individuals in the
population.
For analysing the process of human recovery, published studies
involving the LST were used to estimate the duration of the
cellular immune response based on LST-positivity. Previous
studies reported prevalences of positive LST results among
recovered KA patients (who are expected to be LST-positive)
ranging from 30% to 80% [33]. These studies suggested that the
lowness and variability of LST sensitivity is affected by the
leishmanin antigen suspension chosen. Because an antigen based
on South Asian L. donovani is not available, all LST data refer to L.
infantum or L. major antigens. There is extensive cross-reactivity of
patient responses to heterologous Leishmania species, but as the
variable results underscore, there is a need for better standardisa-
tion and documentation of sensitivity and stability of leishmanin
antigens to obtain more reliable data on the state of cellular
immunity. Effects associated with differing proportions of LST-
Figure 4. Time-dependent effect of reducing the contact rate. We assumed that the feeding cycle duration of the sand fly was doubled by the
intervention from 1/b=4 days to 8 days (scenario 4 in Fig. 3 and Table 5). The intervention lasted for 5 years (grey box). The solid curve shows the
prevalence of KA and the dotted line the prevalence of PKDL.
doi:10.1371/journal.pntd.0001405.g004
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analyses below.
Apart from problems with the antigen (see above), there are in
principle two possibilities to explain a proportion of only 50%
LST-positive individuals (cf. before: .90% LST-positive individ-
uals would be expected under the assumption of life-long LST-
positivity). These two explanations depend on how infection
spreads, as follows: 1) If infection is clustered (e.g., within-
household transmission predominates due to a low rate of
transmission between households) then life-long LST-positivity
may exist on the level of the individual, and a low, ‘average’ LST-
prevalence in the population must result from the demographic
process, i.e., it must result from deaths of LST-positive individuals
and the births of individuals who are LST-negative. 2) If infection
is not clustered, but spreads homogeneously within the human
population, then a low LST-prevalence in the population must
involve loss of the ‘individual’ LST-positivity (as opposed to option
1 where the ‘average’ LST-positivity gets lost). As the birth rate is
not sufficient to explain a prevalence of 50% LST-positive
individuals (see above), we proceeded with the assumption of loss
of LST-positivity. Under this assumption, humans in active L.
donovani transmission foci were infected every one to three years.
A considerable loss of LST positivity has been reported from an
endemic VL focus in Ethiopia [37]. There, the authors concluded
that the presumption of a life-long positive LST reaction may only
hold true under circumstances of continued exposure to infected
sand flies or subclinical infection.
Treatment
A short and effective treatment regimen or early case detection
can reduce the prevalence of KA but has almost no effect on the
incidence of the disease (Fig. 2 and Table 4). Treatment is thus an
intervention that benefits the individual but not the population.
The reason why treatment is not a measure to control the
transmission of infection must be attributed to many asymptom-
atically infected hosts who are - despite a low infectivity for flies -
responsible for the majority of parasite transmissions from humans
to sand flies. As demonstrated by the sensitivity analysis shown in
Fig. 2 and Table 4 (scenario 2), a beneficial effect of treatment on
transmission cannot even be expected under over-optimistic
assumptions; for instance, minimal duration of treatment and
time until treatment start with maximum treatment efficacy. The
KA elimination program aims for less than 1 case per 10,000.
Even under over-optimistic treatment assumptions, this target
would not be reached; the model suggests that elimination of VL
would not succeed if intervention was based on treatment alone.
The contribution of asymptomatic infections on transmission may,
however, be region and strain specific, as apparent from ratios of
asymptomatic infections to KA cases ranging from 6:1 in Brazil to
50:1 in Spain [38].
Vector-related interventions
The current vector-related interventions comprise irregular
indoor spraying and exposure prophylaxis, such as untreated bed
nets. As summarised by [30], indoor insecticide spraying during
the Indian National Malaria Eradication Program between 1958
and 1970 had a drastic impact on transmission of L. donovani.N o
VL cases were reported from the state of Bihar during that period.
However, within months after the program was terminated, the
first cases of KA re-appeared and at the end of 1970, a VL
epidemic struck Bihar. In 1992, another eradication program with
indoor residual DDT spraying resulted in a sharp decline from
1993 until 1999.
Whereby treatment-related interventions only reduce symptom-
atic infection, vector control is also efficient against asymptomatic
infection (Fig. 3 and Table 5). The model predicted that VL may
be eliminated by reducing the vector density by 80%, which seems
to provide serious options for the VL elimination program (results
not shown). Prospects of successful elimination can also be
expressed by the moderate basic reproduction number which this
model predicts with R0=3.94 (see Text S1).
As found during the KalaNet study, the use of treated bed nets
may not provide this efficacy. Indoor density of P. argentipes is
reported in the study to be reduced by 25% in villages that used
treated nets compared with control villages. This intervention
reduced the annual incidence of VL at best to 18.8 cases per
10,000, which is far from the elimination target of less than one
case per 10,000. The authors hypothesised that a substantial
fraction of L. donovani transmission occurring outside the house
may explain the results obtained in the trial [24]. However, two
other studies in the Indian subcontinent showed a much higher
reduction in the sand fly density by means of vector-related
interventions [22,39].
Despite the fact that vector control has the potential to
effectively reduce L. donovani transmission, it must be comple-
mented by the treatment of KA and PKDL cases. The latter can
substantially maintain a reservoir of infection, which can initiate a
new outbreak of disease after vector control is stopped. As the
natural history of L. donovani transmission is a rather slow process
where parasites can persist in humans over a long period, inter-
ventions will show an effect after years, not months, as demon-
strated in Fig. 4. PKDL cases may occur after years, and their final
recovery may take months or years. If vector control is stopped
before parasites are eliminated in the human hosts, then emerging
PKDL cases can initiate a new outbreak of disease as soon as there
are enough sand flies available for transmission. Thus, active case
detection and effective short-course treatment of PKDL combined
with effective vector control are required for VL elimination.
Sensitivity analyses (see also Text S1)
To determine the role of LST-positive individuals (RHC), the
default assumption of 50% LST-positive individuals was varied
between 30% and 70% (76% is the maximum possible value
because 24% of the human population belong to other diagnostic
categories, see above). A low equilibrium prevalence of LST-
positive individuals results from a lower infection rate (or lower
values of correlated parameters, such as the biting rate or the
number of vectors), and a high prevalence of LST-positive indi-
viduals can result from a higher infection rate (or higher values of
correlated parameters, such as the biting rate or the number of
vectors). The only parameter estimate that was affected within the
natural history of infection by this variation of the prevalence of
LST-positive individuals was the rate of loss of cellular immunity
(rHC). The estimate of 1/rHC=307 days of LST-positivity with the
95% confidence interval between 260 and 356 days (see Table 2)
does not support the assumption of a life-long cellular immunity
based on life-long LST-positivity (in technical terms, life-long
LST-positivity would lead to an excessive accumulation of
individuals in state RHC, which is not consistent with the data).
The effects of different prevalences of infected sand flies were
also analysed, as the prevalence of infected sand flies may vary
regionally. The default assumption of IF=0.5% infected sand flies
is based on data from Nepal, whereas higher prevalences have
been observed in India. A higher prevalence of infected sand flies
results from a lower number of flies (NF) or from a higher infection
probability originating from asymptomatic hosts (pF2).
Visceral Leishmaniasis Epidemiology and Control
www.plosntds.org 10 November 2011 | Volume 5 | Issue 11 | e1405We assumed that the period of DAT-positivity is the same for
symptomatic and for asymptomatic cases (1/rHD=1/rHT=74
days). The estimate of rHD (DAT-positivity in asymptomatic cases)
is robust against the assumption that DAT-positivity may last
longer in symptomatic cases [40]. In that investigation antibody
persistence in symptomatic cases was suggested to last on average
about 4 years. Such an increase, however, can be completely
compensated in the model by reducing the period of DAT-
positivity in asymptomatic cases from 74 to 69 days, showing that
the model behaves robust against changes in these assumptions.
A full factorial sensitivity analysis is provided in Fig. S2 in the
Supplement.
Conclusions
Our simulation results show that transmission of L. donovani is
predominantly driven by asymptomatically infected hosts who are
not eligible for treatment. Treatment can reduce the prevalence of
symptomatic disease, but the incidence of KA remains on similar
levels because of an unchanged intensity of transmission. In
contrast to treatment-related interventions, vector-related inter-
ventions have the potential to reduce the prevalence of asymp-
tomatic infections and thus are the intervention of choice from an
epidemiological perspective. Vector control, however, should be
combined with treatment, as PKDL cases can act as reservoirs of
infection. This reservoir function originates from the long period
of nearly two years on average during which putatively recovered
KA patients develop PKDL.
Supporting Information
Figure S1 Full model. In addition to Fig. 1, this diagram
shows the compartments of humans coinfected with HIV. HIV
was modelled independently of infection with L. donovani and
emerged with rate g from all human compartments.
(TIF)
Figure S2 Sensitivity analysis. Sensitivity analysis on the
effects of parameter variations on the stationary solutions of the
model. The scatter plot matrix lists in lines/columns 1 to 8 the
eight estimated parameters (NF, pF2, fHS, fVS, g,1 / cHD,1 / rHD,1 /
rHC), and in lines/columns 9 to 33 the stationary solutions of the
model variables (SH, IHP, IHD, RHD, RHC, IHS, IHT1, RHT, IHT2, RHL,
IHL, SV, IVP, IVD, RVD, RVC, IVS, IVT1, RVT, IVT2, RVL, IVL, SF, EF, IF)
in units of percent of the population, whereby the population of
sand flies varies according to parameter NF. Axes labels and
marginal distributions are placed in the main diagonal. Each point
in a scatter plot represents the stationary solution of one simulation
in 10000. Graphs are coloured according to the likelihood of the
stationary solution: light green or grey for simulations which
significantly differ from the maximum likelihood, and dark green
for simulations which do not (according to a likelihood ratio test
with 8 degrees of freedom). Parameters have been sampled from
triangular distributions with modes given by the estimated mean
and with upper and lower limits given by the 95% confidence
interval for each parameter. Parameters have been sampled
independently and are thus not correlated (see lines/columns 1 to
8). The coefficients of correlations in the table to the right have
been computed from simulations of which the likelihood does not
significantly differ from the maximum likelihood (green dots in the
scatter plots). Main influences of the parameters are (see table to
the right): {NF, pF2},SF, fHS,{IHS, IHT1, RHT, IHT2, RHL, IHL},
fVS,{IVS, IVT1, RVT, IVT2, RVL, IVL}, g,{SV, IVP, IVD, RVD, RVC},
cHD,{IHD, IVD}, 1/rHD,{RHD, IHP ; RVD}, 1/rHC,{SH, RHC, SV,
RVC}. For interrelationships between stationary solutions of the
variables see Discussion in the main text.
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